- Home
- BRKR vs TGTX Comparison
BRKR vs TGTX Comparison
Compare BRKR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- TGTX
- Stock Information
- Founded
- BRKR 1960
- TGTX 1993
- Country
- BRKR United States
- TGTX United States
- Employees
- BRKR N/A
- TGTX N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BRKR Industrials
- TGTX Health Care
- Exchange
- BRKR Nasdaq
- TGTX Nasdaq
- Market Cap
- BRKR 5.3B
- TGTX 4.2B
- IPO Year
- BRKR 2000
- TGTX 1995
- Fundamental
- Price
- BRKR $30.91
- TGTX $32.16
- Analyst Decision
- BRKR Buy
- TGTX Strong Buy
- Analyst Count
- BRKR 11
- TGTX 4
- Target Price
- BRKR $50.00
- TGTX $42.50
- AVG Volume (30 Days)
- BRKR 4.3M
- TGTX 2.1M
- Earning Date
- BRKR 11-04-2025
- TGTX 11-03-2025
- Dividend Yield
- BRKR 0.65%
- TGTX N/A
- EPS Growth
- BRKR N/A
- TGTX N/A
- EPS
- BRKR 0.52
- TGTX 0.36
- Revenue
- BRKR $3,442,800,000.00
- TGTX $454,069,000.00
- Revenue This Year
- BRKR $4.62
- TGTX $82.58
- Revenue Next Year
- BRKR $1.93
- TGTX $44.99
- P/E Ratio
- BRKR $59.32
- TGTX $89.15
- Revenue Growth
- BRKR 10.36
- TGTX 30.96
- 52 Week Low
- BRKR $28.53
- TGTX $21.16
- 52 Week High
- BRKR $72.94
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- BRKR 41.52
- TGTX 57.84
- Support Level
- BRKR $30.31
- TGTX $31.34
- Resistance Level
- BRKR $34.22
- TGTX $32.57
- Average True Range (ATR)
- BRKR 1.34
- TGTX 1.13
- MACD
- BRKR 0.05
- TGTX 0.54
- Stochastic Oscillator
- BRKR 32.65
- TGTX 76.20
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.